Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PTIX Stock Summary
Top 10 Correlated ETFs
PTIX
In the News
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day.
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023.
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022.
Protagenic Therapeutics Shares Increase Over 10% Pre-Market: Why It Happened
The shares of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 10% pre-market. This is why it happened.
Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End
Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression.
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.
7 Best Penny Stocks to Buy Now for Potential 10X Gains
Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.
PTIX Stock Price: Over 25% Increase Pre-Market Explanation
The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 25% pre-market. These are the details.
Best Biotech Penny Stocks in June 2021? Check These 4 Out
Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?
4 Biotech Penny Stocks That You Need to Know About
These biotech penny stocks pushed up big today; but are they worth it? The post 4 Biotech Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PTIX Financial details
PTIX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1 | -0.69 | -1.08 | -1.35 | -0.83 | |
Operating cash flow per share | -0.42 | -0.19 | -0.52 | -0.76 | -0.46 | |
Free cash flow per share | -0.42 | -0.19 | -0.52 | -0.76 | -0.46 | |
Cash per share | 0.24 | 0.31 | 0.26 | 2.81 | 1.85 | |
Book value per share | -0.08 | -0.25 | -0.44 | 2.7 | 1.6 | |
Tangible book value per share | -0.08 | -0.25 | -0.44 | 2.7 | 1.6 | |
Share holders equity per share | -0.08 | -0.25 | -0.44 | 2.7 | 1.6 | |
Interest debt per share | 0 | 0.12 | 0.63 | 0.22 | 0.11 | |
Market cap | 5.13M | 3.62M | 2.71M | 20.42M | 6.91M | |
Enterprise value | 4.77M | 3.1M | 3.42M | 20.19M | 7.04M | |
P/E ratio | -2.01 | -2.05 | -0.97 | -4.09 | -1.92 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -4.79 | -7.41 | -2.01 | -7.3 | -3.47 | |
PFCF ratio | -4.79 | -7.41 | -2.01 | -7.3 | -3.46 | |
P/B Ratio | -24.33 | -5.7 | -2.36 | 2.05 | 1 | |
PTB ratio | -24.33 | -5.7 | -2.36 | 2.05 | 1 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.31 | -1.49 | -1.34 | -4.92 | -2.09 | |
EV to operating cash flow | -4.45 | -6.35 | -2.53 | -7.22 | -3.53 | |
EV to free cash flow | -4.45 | -6.35 | -2.53 | -7.22 | -3.53 | |
Earnings yield | -0.5 | -0.49 | -1.03 | -0.24 | -0.52 | |
Free cash flow yield | -0.21 | -0.13 | -0.5 | -0.14 | -0.29 | |
Debt to equity | 0 | -0.44 | -1.19 | 0.03 | 0.05 | |
Debt to assets | 0 | 0.33 | 1.56 | 0.03 | 0.04 | |
Net debt to EBITDA | 0.18 | 0.25 | -0.28 | 0.05 | -0.04 | |
Current ratio | 0.77 | 0.7 | 1.34 | 13.83 | 7.18 | |
Interest coverage | -829.44 | -131.32 | -10.36 | -8.33 | -25.88 | |
Income quality | 0.42 | 0.28 | 0.53 | 0.62 | 0.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -60.17 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.36 | 1.96 | 3.29 | 9.06 | 5.48 | |
ROIC | 13.06 | 5.93 | -12.49 | -0.44 | -0.5 | |
Return on tangible assets | -3.67 | -2.1 | -3.18 | -0.45 | -0.45 | |
Graham Net | -0.11 | -0.26 | -0.53 | 2.51 | 1.59 | |
Working capital | -211.49K | -355.29K | 224.06K | 10.26M | 6.92M | |
Tangible asset value | -210.88K | -634.37K | -1.15M | 9.94M | 6.92M | |
Net current asset value | -211.49K | -634.66K | -1.15M | 9.94M | 6.92M | |
Invested capital | 0 | -0.44 | -1.19 | 0.03 | 0.05 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 26.26K | 44.26K | 89.01K | 210.4K | 474.33K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 38.93K | 181.05K | 0 | 8.15M | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.01 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 12.13 | 2.79 | 2.43 | -0.5 | -0.52 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.21 | -0.14 | -0.17 | -0.28 | -0.32 | |
Operating cash flow per share | -0.12 | -0.04 | -0.09 | -0.35 | -0.15 | |
Free cash flow per share | -0.12 | -0.04 | -0.09 | -0.35 | -0.16 | |
Cash per share | 1.89 | 1.85 | 1.77 | 1.4 | 1.22 | |
Book value per share | 1.71 | 1.6 | 1.49 | 1.25 | 0.96 | |
Tangible book value per share | 1.71 | 1.6 | 1.49 | 1.25 | 0.96 | |
Share holders equity per share | 1.71 | 1.6 | 1.49 | 1.25 | 0.96 | |
Interest debt per share | 0.08 | 0.09 | 0.09 | 0.1 | 0.1 | |
Market cap | 9.85M | 6.91M | 7.47M | 8.79M | 7.97M | |
Enterprise value | 10.01M | 7.04M | 7.7M | 8.97M | 8.24M | |
P/E ratio | -2.75 | -2.84 | -2.56 | -1.82 | -1.43 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -18.41 | -38.18 | -20.09 | -5.74 | -12.15 | |
PFCF ratio | -18.41 | -37.81 | -20.09 | -5.74 | -11.2 | |
P/B Ratio | 1.33 | 1 | 1.16 | 1.62 | 1.92 | |
PTB ratio | 1.33 | 1 | 1.16 | 1.62 | 1.92 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.36 | -12.49 | -11.29 | -8.47 | -6.15 | |
EV to operating cash flow | -18.71 | -38.9 | -20.71 | -5.85 | -12.56 | |
EV to free cash flow | -18.71 | -38.51 | -20.71 | -5.85 | -11.57 | |
Earnings yield | -0.09 | -0.09 | -0.1 | -0.14 | -0.18 | |
Free cash flow yield | -0.05 | -0.03 | -0.05 | -0.17 | -0.09 | |
Debt to equity | 0.04 | 0.05 | 0.06 | 0.07 | 0.1 | |
Debt to assets | 0.04 | 0.04 | 0.05 | 0.06 | 0.08 | |
Net debt to EBITDA | -0.18 | -0.23 | -0.34 | -0.17 | -0.2 | |
Current ratio | 14.91 | 7.18 | 6.12 | 4.6 | 4.2 | |
Interest coverage | -28.92 | -20.52 | -23.65 | -36.18 | -44.8 | |
Income quality | 0.58 | 0.3 | 0.52 | 1.27 | 0.47 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0.09 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -60.17 | 0 | 0 | -39.33 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 2.82 | 2.25 | 2.37 | 2.8 | 2.64 | |
ROIC | -0.12 | -0.09 | -0.11 | -0.2 | -0.33 | |
Return on tangible assets | -0.11 | -0.08 | -0.09 | -0.17 | -0.26 | |
Graham Net | 1.68 | 1.59 | 1.48 | 1.05 | 0.92 | |
Working capital | 7.7M | 6.92M | 6.41M | 5.41M | 4.1M | |
Tangible asset value | 7.38M | 6.92M | 6.41M | 5.41M | 4.15M | |
Net current asset value | 7.38M | 6.92M | 6.41M | 5.41M | 4.1M | |
Invested capital | 0.04 | 0.05 | 0.06 | 0.07 | 0.1 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 236.82K | 404.52K | 422.29K | 166.52K | 200.85K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 2.01M | 174.87K | 156.43K | 15.45K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.12 | -0.09 | -0.11 | -0.22 | -0.34 | |
Capex per share | 0 | 0 | 0 | 0 | -0.01 |
PTIX Frequently Asked Questions
What is Protagenic Therapeutics, Inc. stock symbol ?
Protagenic Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol PTIX
What is Protagenic Therapeutics, Inc. stock quote today ?
Protagenic Therapeutics, Inc. stock price is $1.82 today.
Is Protagenic Therapeutics, Inc. stock public?
Yes, Protagenic Therapeutics, Inc. is a publicly traded company.